Oncolytic viruses (OVs) are picking up steam as prospective therapeutic platforms for cancer treatment. Besides direct oncolysis, the intrinsic stimulation of both innate and adaptive immune responses is an important appealing feature of oncolytic virus therapy. And with the advance in technologies such as CRISPR, OVs now can be genetically modified to boost anti-tumor immunity, and further improve immune response.
Powered by OncoVirapyTM platform, reverse genetics technology, and bacterial artificial chromosome (BAC) technology, the scientist team at Creative Biolabs can deliver engineered oncolytic viruses fulfilling the specific demands of research, preclinical study, and drug development. Creative Biolabs offers one-stop oncolytic virus engineering services that cover pathogenicity and immunogenicity manipulation, antibody expressing, cytokine/chemokine expressing, and immune checkpoint inhibitor expressing.
Antibody-expressing oncolytic virus is one of the hot topics. Creative Biolabs can customize oncolytic viruses with tumor-targeting recombinant monoclonal antibodies (mAbs) and immunomodulatory mAbs, and promises reduced risk of toxicity with a short turnaround time and an equitable price.
Another featured service is the customized cytokine/chemokine-expressing oncolytic virus engineering. The scientist team keeps up with the latest discoveries and is expert in expressing potential cytokine-expressing vectors including chemokine ligand 5 (CCL5) and interleukin 2 (IL-2).
As the identification and targeting of immune checkpoints is becoming a novel approach to activating sustained anti-tumor immunity, Creative Biolabs is also dedicated to designing and producing immune checkpoint inhibitor-expressing oncolytic viruses. The team is familiar with antibody-blocking checkpoint proteins including anti-programmed cell death-1 (PD-1) and anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4), which have been approved to treat cancer, and is looking forward to partnering with global clients to exploring other kinds, such as TIM- 3 and LAG-3.
“We would like to highlight our OncoVirapy(TM) platform, a self-established systemic R&D mode in oncotherapy. We have integrated the technologies of viral biology, immunology, and genetic engineering, and have accumulated experience from previous cases to provide comprehensive services for developing engineered oncolytic virus, covering oncolytic virus engineering, construction, in vitro and in vivo assays, and manufacture,” said a scientist in the expert team.
Detailed information about the platforms and services can be found on https://www.creative-biolabs.com/oncolytic-virus.
About Creative Biolabs
Empowered by leading technology and years of experience in biomedical science, Creative Biolabs is dedicated to offering comprehensive, end-to-end oncolytic virus therapy development services. The whole pipeline covers oncolytic virus engineering, in vitro validation study, in vivo preclinical study, disease-specific oncolytic virotherapy development, etc.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Florida Times Daily journalist was involved in the writing and production of this article.